Novo Nordisk signs Orbis Medicines discovery deal worth up to $1.4 billion
The multi-target partnership covers Orbis's macrocycle platform, with most value tied to milestones.
TR
By Tom Reyes · Markets Editor
Sep 17 07:00 ETSource: finance.yahoo.com
The wire
- 01Orbis Medicines entered a multi-target drug discovery partnership with Novo Nordisk valued at up to $1.4 billion.
- 02Signals Novo's continued investment in oral macrocycle discovery platforms.
- 03Targets and upfront payment terms were not detailed.
From the source
Read at news.google.comOrbis Medicines Enters Multi-Target Drug Discovery Partnership with Novo Nordisk Worth up to USD 1.4 Billion